The Role of Complementary and Alternative Therapies in Pediatric Diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 4, 2009, Pages 791-810

  Shapiro, Sofia ^a   Rapaport, Robert ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alternative medicine; Complementary medicine; Diabetes; Integrative medicine; Pediatrics

Indexed keywords

ALPHA TOCOPHEROL; CALCITRIOL; CHROMIUM; COD LIVER OIL; COLECALCIFEROL; CYANOCOBALAMIN; CYCLOSPORIN; DOCOSAHEXAENOIC ACID; FOLIC ACID; ICOSAPENTAENOIC ACID; INSULIN; NICOTINAMIDE; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PYRIDOXAMINE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; THIOCTIC ACID; VITAMIN B COMPLEX; VITAMIN D; ZINC;

ABSENCE OF SIDE EFFECTS; ALTERNATIVE MEDICINE; AMINOTRANSFERASE BLOOD LEVEL; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD HEALTH CARE; CINNAMON; CLINICAL TRIAL; CULTURAL FACTOR; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FLUSHING; GLYCEMIC CONTROL; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HOMEOPATHY; HUMAN; HYPERCALCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOPENIA; LIVER DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT DURATION;

CHILD; CINNAMOMUM ZEYLANICUM; COD LIVER OIL; COMPLEMENTARY THERAPIES; DIABETES MELLITUS; FATTY ACIDS; HUMANS; METALS; NIACINAMIDE; PEDIATRICS; VITAMINS;

EID: 70449970795     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.09.004     Document Type: Review

References (75)

1. Pleis J.R., and Lucas J.W. Summary health statistics for US adults: National Health Interview Survey, 2007. Vital Health Stat 1 240 (2009) 1-159
2. Thinking about CAM therapies for young people. CAM at the NIH 14 1 (2007) 1, 4-7
3. Kemper K.J., Vohra S., Walls R., et al. The use of complementary and alternative medicine in pediatrics. Pediatrics 122 6 (2008) 1374-1386
4. National Institutes of Health. National Center for Complementary and Alternative Medicine. Available at: http://ncam.nih.gov. Accessed August 19, 2009.
5. Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. 1994; Public Law Number:103-417.
6. McCann L.J., and Newell S.J. Survey of paediatric complementary and alternative medicine use in health and chronic illness. Arch Dis Child 91 2 (2006) 173-174
7. Samdup D.Z., Smith R.G., and Il Song S. The use of complementary and alternative medicine in children with chronic medical conditions. Am J Phys Med Rehabil 85 10 (2006) 842-846
8. Dannemann K., Hecker W., Haberland H., et al. Use of complementary and alternative medicine in children with type 1 diabetes mellitus-prevalence, patterns of use, and costs. Pediatr Diabetes 9 3 Pt 1 (2008) 228-235
9. Miller J.L., Binns H.J., and Brickman W.J. Complementary and alternative medicine use in children with type 1 diabetes: a pilot survey of parents. Explore (NY) 4 5 (2008) 311-314
10. Arykan D., Sivrikaya S.K., and Olgun N. Complementary alternative medicine use in children with type 1 diabetes mellitus in Erzurum, Turkey. J Clin Nurs 18 15 (2009) 2136-2144
11. Jean D., and Cyr C. Use of complementary and alternative medicine in a general pediatric clinic. Pediatrics 120 1 (2007) e138-e141
12. Pozzilli P., Visalli N., Boccuni M.L., et al. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group. Diabet Med 11 1 (1994) 98-104
13. Pozzilli P., Visalli N., Signore A., et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 38 7 (1995) 848-852
14. Visalli N., Cavallo M.G., Signore A., et al. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). Diabetes Metab Res Rev 15 3 (1999) 181-185
15. Crino A., Schiaffini R., Ciampalini P., et al. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab 18 8 (2005) 749-754
16. Pozzilli P., Visalli N., Cavallo M.G., et al. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). Eur J Endocrinol 137 3 (1997) 234-239
17. Crino A., Schiaffini R., Manfrini S., et al. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur J Endocrinol 150 5 (2004) 719-724
18. Pitocco D., Crino A., Di Stasio E., et al. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med 23 8 (2006) 920-923
19. Elliott R.B., Pilcher C.C., Stewart A., et al. The use of nicotinamide in the prevention of type 1 diabetes. Ann N Y Acad Sci 696 (1993) 333-341
20. Lampeter E.F., Klinghammer A., Scherbaum W.A., et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 47 6 (1998) 980-984
21. Gale E.A., Bingley P.J., Emmett C.L., et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363 9413 (2004) 925-931
22. Jain S.K. Vitamin B6 (pyridoxamine) supplementation and complications of diabetes. Meta 56 2 (2007) 168-171
23. Pena A.S., Wiltshire E., Gent R., et al. Folic acid improves endothelial function in children and adolescents with type 1 diabetes. J Pediatr 144 4 (2004) 500-504
24. MacKenzie K.E., Wiltshire E.J., Gent R., et al. Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus. Pediatrics 118 1 (2006) 242-253
25. Mathieu C., Gysemans C., Giulietti A., et al. Vitamin D and diabetes. Diabetologia 48 7 (2005) 1247-1257
26. Driver J.P., Foreman O., Mathieu C., et al. Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D(3) and 1alpha-hydroxyvitamin D(3) on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet. Clin Exp Immunol 151 1 (2008) 76-85
27. Littorin B., Blom P., Scholin A., et al. Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 49 12 (2006) 2847-2852
28. Pozzilli P., Manfrini S., Crino A., et al. Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. Horm Metab Res 37 11 (2005) 680-683
29. Greer R.M., Rogers M.A., Bowling F.G., et al. Australian children and adolescents with type 1 diabetes have low vitamin D levels. Med J Aust 187 1 (2007) 59-60
30. Zipitis C.S., and Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 93 6 (2008) 512-517
31. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 42 1 (1999) 51-54
32. Hughes D.A., and Pinder A.C. n-3 Polyunsaturated fatty acids inhibit the antigen-presenting function of human monocytes. Am J Clin Nutr 71 Suppl 1 (2000) 357S-360S
33. Endres S., Meydani S.N., Ghorbani R., et al. Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. J Leukoc Biol 54 6 (1993) 599-603
34. Stene L.C., Joner G., and Norwegian Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 78 6 (2003) 1128-1134
35. Stene L.C., Ulriksen J., Magnus P., et al. Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia 43 9 (2000) 1093-1098
36. Deckelbaum R.J., Leaf A., Mozaffarian D., et al. Conclusions and recommendations from the symposium, beyond cholesterol: prevention and treatment of coronary heart disease with n-3 Fatty acids. Am J Clin Nutr 87 6 (2008) 2010S-2012S
37. Norris J.M., Yin X., Lamb M.M., et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 298 12 (2007) 1420-1428
38. Lorini R., Minicucci L., Napoli F., et al. Screening for type 1 diabetes genetic risk in newborns of continental Italy. Primary prevention (Prevefin Italy)-preliminary data. Acta Biomed 76 Suppl 3 (2005) 31-35
39. Chase H.P., Butler-Simon N., Garg S., et al. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33 7 (1990) 444-446
40. Chase P.H., Lescheck E., Rafkin-Mervis L., et al. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes: a pilot trial. ICAN 1 98 (2009) 99-107
41. Type 1 Diabetes trial net. Available at:. http://www.diabetestrialnet.org/patientinfo/studies/nutritional/htm Accessed July 27, 2009
42. Jain S.K., McVie R., and Smith T. Vitamin E supplementation restores glutathione and malondialdehyde to normal concentrations in erythrocytes of type 1 diabetic children. Diabetes Care 23 9 (2000) 1389-1394
43. Jain S.K., McVie R., Jaramillo J.J., et al. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type I diabetic patients. J Am Coll Nutr 15 5 (1996) 458-461
44. Giannini C., Lombardo F., Curro F., et al. Effects of high-dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type 1 diabetes mellitus. Diabetes Metab Res Rev 23 7 (2007) 539-546
45. Chiarelli F., Santilli F., Sabatino G., et al. Effects of vitamin E supplementation on intracellular antioxidant enzyme production in adolescents with type 1 diabetes and early microangiopathy. Pediatr Res 56 5 (2004) 720-725
46. Bursell S.E., Clermont A.C., Aiello L.P., et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 22 8 (1999) 1245-1251
47. Uusitalo L., Kenward M.G., Virtanen S.M., et al. Intake of antioxidant vitamins and trace elements during pregnancy and risk of advanced beta cell autoimmunity in the child. Am J Clin Nutr 88 2 (2008) 458-464
48. Qin B., Nagasaki M., Ren M., et al. Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats. Diabetes Res Clin Pract 62 3 (2003) 139-148
49. Kim S.H., Hyun S.H., and Choung S.Y. Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. J Ethnopharmacol 104 1-2 (2006) 119-123
50. Lakshmi B.S., Sujatha S., Anand S., et al. Cinnamic acid, from the bark of Cinnamomum cassia, regulates glucose transport via activation of GLUT4 on L6 myotubes in a phosphatidylinositol 3-kinase-independent manner. J Diabetes 1(2) (2009) 99, 100-106
51. Mang B., Wolters M., Schmitt B., et al. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest 36 5 (2006) 340-344
52. Vanschoonbeek K., Thomassen B.J., Senden J.M., et al. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr 136 4 (2006) 977-980
53. Altschuler J.A., Casella S.J., MacKenzie T.A., et al. The effect of cinnamon on A1C among adolescents with type 1 diabetes. Diabetes Care 30 4 (2007) 813-816
54. Baker W.L., Gutierrez-Williams G., White C.M., et al. Effect of cinnamon on glucose control and lipid parameters. Diabetes Care 31 1 (2008) 41-43
55. Davis C.M., and Vincent J.B. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 36 15 (1997) 4382-4385
56. Kordella T. Research profile. Chromium. Can it help kids with type 2? Sushil K. Jain, PhD. Diabetes Forecast 57 7 (2004) 83-85
57. Yeh G.Y., Eisenberg D.M., Kaptchuk T.J., et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26 4 (2003) 1277-1294
58. Kleefstra N., Houweling S.T., Bakker S.J., et al. Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 30 5 (2007) 1092-1096
59. Singer G.M., and Geohas J. The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial. Diabetes Technol Ther 8 6 (2006) 636-643
60. Albarracin C.A., Fuqua B.C., Evans J.L., et al. Chromium picolinate and biotin combination improves glucose Meta in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 24 1 (2008) 41-51
61. Geohas J., Daly A., Juturu V., et al. Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Am J Med Sci 333 3 (2007) 145-153
62. Wang Z.Q., Qin J., Martin J., et al. Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Meta 56 12 (2007) 1652-1655
63. Song M.K., Hwang I.K., Rosenthal M.J., et al. Anti-hyperglycemic activity of zinc plus cyclo (his-pro) in genetically diabetic Goto-Kakizaki and aged rats. Exp Biol Med (Maywood) 228 11 (2003) 1338-1345
64. Hagglof B., Hallmans G., Holmgren G., et al. Prospective and retrospective studies of zinc concentrations in serum, blood clots, hair and urine in young patients with insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 102 1 (1983) 88-95
65. Pedrosa L.F., Ferreira S.R., Cesarini P.R., et al. Influence of glycemic control on zinc urinary excretion in patients with type 1 diabetes. Diabetes Care 22 2 (1999) 362-363
66. Anderson R.A., Roussel A.M., Zouari N., et al. Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr 20 3 (2001) 212-218
67. Chausmer A.B. Zinc, insulin and diabetes. J Am Coll Nutr 17 2 (1998) 109-115
68. de Sena K.C., Arrais R.F., das Gracas Almeida M., et al. Effects of zinc supplementation in patients with type 1 diabetes. Biol Trace Elem Res 105 1-3 (2005) 1-9
69. Cunningham J.J., Fu A., Mearkle P.L., et al. Hyperzincuria in individuals with insulin-dependent diabetes mellitus: concurrent zinc status and the effect of high-dose zinc supplementation. Meta 43 12 (1994) 1558-1562
70. Uusitalo L., Nevalainen J., Niinisto S., et al. Serum alpha- and gamma-tocopherol concentrations and risk of advanced beta cell autoimmunity in children with HLA-conferred susceptibility to type 1 diabetes mellitus. Diabetologia 51 5 (2008) 773-780
71. Ziegler D., Nowak H., Kempler P., et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 21 2 (2004) 114-121
72. Huang E.A., and Gitelman S.E. The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatr Diabetes 9 3 Pt 2 (2008) 69-73
73. Vanelli M., Chiari G., Gugliotta M., et al. [Diabetes and alternative medicine: diabetic patients experiences with Ayur-Ved, "clinical ecology" and "cellular nutrition" methods]. Minerva Pediatr 54 2 (2002) 165-169 [in Italian]
74. Bhowmick S.K., Hundley O.T., and Rettig K.R. Severe hypernatremia and hyperosmolality exacerbated by an herbal preparation in a patient with diabetic ketoacidosis. Clin Pediatr (Phila) 46 9 (2007) 831-834
75. Glauber B. Faith, medicine collide, and a young girl dies: parents chose to pray rather than get medical help for sick child. Journal Sentinel Online, Milwaukee Wisconsin (March 27, 2008). http://www.jsonline.com/news/wisconsin/29545619.html Accessed August 19, 2009